Research programme: ear and nose disorder therapeutics - Auris Medical

Drug Profile

Research programme: ear and nose disorder therapeutics - Auris Medical

Alternative Names: AM 123; AM-102 - Auris Medical

Latest Information Update: 27 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Auris Medical; Kings College London
  • Developer Auris Medical
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Nose disorders; Tinnitus

Most Recent Events

  • 23 Oct 2015 Auris Medical and King's College of London agree to co-develop AM 102 for Tinnitus
  • 15 Sep 2014 Preclinical trials in Nose disorders in Switzerland (unspecified route)
  • 15 Sep 2014 Preclinical trials in Tinnitus in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top